Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Covista (ATGE) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Covista (ATGE) over the last 17 years, with Q4 2025 value amounting to $56.3 million.

  • Covista's Cash & Equivalents fell 7098.29% to $56.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $56.3 million, marking a year-over-year decrease of 7098.29%. This contributed to the annual value of $199.6 million for FY2025, which is 898.52% down from last year.
  • Covista's Cash & Equivalents amounted to $56.3 million in Q4 2025, which was down 7098.29% from $264.7 million recorded in Q3 2025.
  • Over the past 5 years, Covista's Cash & Equivalents peaked at $819.0 million during Q2 2021, and registered a low of $56.3 million during Q4 2025.
  • For the 5-year period, Covista's Cash & Equivalents averaged around $326.1 million, with its median value being $264.7 million (2024).
  • In the last 5 years, Covista's Cash & Equivalents surged by 38162.91% in 2021 and then tumbled by 7098.29% in 2025.
  • Over the past 5 years, Covista's Cash & Equivalents (Quarter) stood at $275.4 million in 2021, then fell by 25.1% to $206.3 million in 2022, then decreased by 11.34% to $182.9 million in 2023, then increased by 6.05% to $194.0 million in 2024, then tumbled by 70.98% to $56.3 million in 2025.
  • Its Cash & Equivalents stands at $56.3 million for Q4 2025, versus $264.7 million for Q3 2025 and $199.6 million for Q2 2025.